@FiercePharma: U.K. cost watchdog about-faces on BMS and AZN's Forxiga, recommending it for some diabetes patients. Story | Follow @FiercePharma
@EricPFierce: Will Hospira never learn? FDA warning letter says some problems at India plant same as those recently noted at Rocky Mount. More | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: FDA is importing TPN to ease drug shortage. Story | Follow @CarlyHFierce
> Endo Health Solutions ($ENDP) said two of its top executives, CFO Alan G. Levin and COO Julie McHugh, are leaving the company; no replacements have yet been named. Release | Report
> Eli Lilly ($LLY) sued Perrigo ($PRGO) for infringing its patent on the low-testosterone treatment Axiron, seeking to block generic versions of the drug. Report
> Pfizer ($PFE) issued $4 billion in bonds, in its first dollar-denominated debt issue since 2009. Report
> Analysts hiked their price targets on Valeant Pharmaceuticals ($VRX) on the strength of its newly agreed acquisition of Bausch + Lomb. Report
> Royalty Pharma contends that recent stock sales by Elan ($ELN) investors signal that shareholders support its buyout proposal. Report
> Germany's Stada Arzneimittel said it successfully placed €350 million worth of corporate bonds. Report
@FierceMedDev: GE snags ultrasound repair business. More | Follow @FierceMedDev
@DamianFierce: As GSK trumpets two new FDA approvals, France's bioMérieux is poised to cash in on companion diagnostics. More | Follow @DamianFierce
@MichaelGFierce: Devicemakers balk at FDA's recall guidelines. Item | Follow @MichaelGFierce
> Sequenom reaches into France with prenatal Dx. Report
> GE snags ultrasound repair business. Article
> Devicemakers balk at FDA's recall guidelines. More
> Edwards hit with FDA warning letter. News
> Abbott's Absorb takes India by storm. Story
Biotech News
@FierceBiotech: UCLA slams the door on GlaxoSmithKline's latest R&D competition. More | Follow @FierceBiotech
@JohnCFierce: ICYMI: Updated: GlaxoSmithKline gains FDA OK on two genetically targeted melanoma drugs. Report | Follow @JohnCFierce
@RyanMFierce: Biogen Idec appears to be playing the long game with delayed EU launch of Tecfidera, and that could benefit even short-term investors. | Follow @RyanMFierce
@EmilyMFierce: Newest feature at @FierceBiotech: Top 10 experimental cancer drugs - 2013. Special Report | Follow @EmilyMFierce
> San Diego biotech files $23M IPO for gastroparesis PhIII. Report
> Pfizer taps UCSF for small-molecule drug discovery. Story
> ASCO presentations portend future shock of immunotherapy drug prices. Article
> Elan execs ready fallback plan as Royalty attacks 'jumble' of deals. News
Pharma Manufacturing News
> Pfizer sells King Pharma plant to UPM Pharmaceuticals. More
> UCB sells New York plant to Unither. News
> FDA turns to Fresenius to help relieve TPN shortage. Story
> New problems with Hospira's Indian plant reminiscent of Rocky Mount. Article
> J&J appeals OTC plant license revocation in India. Item
Vaccines News
> H7N9 shows resistance to Roche's Tamiflu. News
> Chinese HFMD vaccine impresses in Phase III. Report
> Gates-inspired gene therapy gives pandemic protection. Story
> Study links GSK's swine flu vaccine to narcolepsy in adults. Article
> Researchers seek fresh approach to HIV vaccine. More
And Finally... A new analysis from the American Medical Association found that children who have used ADHD treatments are no less likely to abuse drugs later in life than those who haven't. Report